卡瑞利珠单抗联合传统化疗在晚期非鳞非小细胞肺癌中的临床疗效

The clinical efficacy of camrelizumab plus carboplatin and pemetrexed in the treatment of advanced non-squamous non-small cell lung cancer

目的:观察卡瑞利珠单抗联合卡铂和培美曲塞方案治疗晚期非鳞非小细胞肺癌(NSCLC)的临床疗效。方法:选取2019年6月~2020年12月在我院收治的晚期非鳞NSCLC患者80例,随机接受卡铂和培美曲塞方案联合卡瑞利珠单抗(观察组)或不联合(对照组)治疗,观察治疗效果。结果:观察组和对照组患者的部分缓解率分别为57.5%和35%,临床疗效有效率分别为82.5%和60%;观察组部分缓解率、临床疗效明显优于对照组。观察组和对照组患者的总生存时间分别为6.35±3.17个月和6.06±3.06个月,无进展生存时间分别为5.92±3.16个月和5.75±3.09个月;观察组总生存时间、无进展生存时间显著长于对照组。治疗3个月后,观察组CEA和CA125水平明显低于对照组。两组患者均未出现严重不良反应。结论:卡瑞利珠单抗联合卡铂和培美曲塞的治疗方案在晚期非鳞NSCLC患者中总体有效率较高,患者耐受性良好,值得进一步推广使用。

Objective To observe the clinical efficacy of camrelizumab plus carboplatin and pemetrexed in the treatment of advanced non-squamous non-small cell lung cancer(NSCLC).Methods A total of 80 patients with advanced non-squamous NSCLC who were admitted to our hospital from June 2019 to December 2020 were selected.All patients were randomized to receive carboplatin and pemetrexed combined with camrelizumab(observation group)or not(control group),and the clinical treatment effect was observed.Results The objective response rates of the observation group and the control group were 57.5%and 35%,and the clinical efficacy rates were 82.5%and 60%,respectively.The partial remission rate and clinical efficacy of the observation group were significantly better than those of the control group.The overall survival time of patients in the observation and control group was 6.35±3.17 and 6.06±3.06 months,and the progression-free survival time was 5.92±3.16 and 5.75±3.09 months,respectively.The overall survival time and progression-free survival time of the observation group were significantly longer than those of the control group.The difference was statistically significant.After 3 months of treatment,the levels of CEA and CA125 in the observation group were significantly lower than those in the control group.There were no serious adverse reactions in the two groups.Conclusion The treatment plan of camrelizumab plus carboplatin and pemetrexed has a higher overall effective rate in patients with advanced non-squamous NSCLC,and the patients are well tolerated,and it is worthy of further promotion.